Intra-Cellular Therapies, Inc.
NASDAQ:ITCI
75.38 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 462.175 | 249.132 | 81.708 | 22.531 | 0.061 | 0 | 0.246 | 0.331 | 0.091 | 0.577 | 2.737 | 3.118 |
| Cost of Revenue
| 33.745 | 20.443 | 8.035 | 1.895 | 0.477 | 0.369 | 79.419 | 93.832 | 0.14 | 21.226 | 23.028 | 15.486 |
| Gross Profit
| 428.43 | 228.689 | 73.673 | 20.636 | -0.417 | -0.369 | -79.173 | -93.501 | -0.048 | -20.649 | -20.291 | -12.368 |
| Gross Profit Ratio
| 0.927 | 0.918 | 0.902 | 0.916 | -6.872 | 0 | -322.056 | -282.734 | -0.528 | -35.768 | -7.413 | -3.967 |
| Reseach & Development Expenses
| 180.142 | 134.715 | 88.846 | 65.782 | 89.125 | 132.167 | 79.419 | 93.832 | 87.718 | 21.226 | 23.028 | 15.486 |
| General & Administrative Expenses
| 317.664 | 272.982 | 190.111 | 150.063 | 64.948 | 30.1 | 23.667 | 24.758 | 18.187 | 10.338 | 5.976 | 4.035 |
| Selling & Marketing Expenses
| 92.2 | 85.8 | 82.5 | 36.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 409.864 | 358.782 | 272.611 | 186.363 | 64.948 | 30.1 | 23.667 | 24.758 | 18.187 | 10.338 | 5.976 | 4.035 |
| Other Expenses
| 0 | -1.182 | -2.095 | -0.282 | 0 | 0 | -0.246 | -0.331 | -0.061 | -0.03 | 0 | 0 |
| Operating Expenses
| 587.811 | 492.315 | 359.361 | 251.863 | 154.072 | 162.267 | 103.086 | 118.59 | 105.905 | 31.564 | 29.004 | 19.521 |
| Operating Income
| -159.381 | -263.626 | -285.688 | -231.228 | -154.012 | -162.267 | -102.84 | -118.259 | -105.814 | -30.987 | -26.267 | -16.403 |
| Operating Income Ratio
| -0.345 | -1.058 | -3.496 | -10.263 | -2,540.905 | 0 | -418.326 | -357.6 | -1,158.159 | -53.675 | -9.597 | -5.261 |
| Total Other Income Expenses Net
| 20.343 | 7.376 | 1.568 | 4.235 | 6.291 | 7.141 | 4.006 | 2.898 | 1.022 | 0.297 | -0.583 | -0.154 |
| Income Before Tax
| -139.038 | -256.25 | -284.12 | -226.992 | -147.721 | -155.126 | -98.834 | -115.361 | -104.792 | -30.69 | -26.85 | -16.558 |
| Income Before Tax Ratio
| -0.301 | -1.029 | -3.477 | -10.075 | -2,437.11 | 0 | -402.032 | -348.835 | -1,146.968 | -53.161 | -9.81 | -5.31 |
| Income Tax Expense
| 0.636 | 0.006 | 0.006 | 0.014 | 0.002 | 0.002 | -1.061 | 1.066 | 0.002 | 0.002 | 0.018 | 0.033 |
| Net Income
| -139.674 | -256.256 | -284.126 | -227.006 | -147.722 | -155.127 | -97.773 | -116.426 | -104.793 | -30.691 | -26.868 | -16.591 |
| Net Income Ratio
| -0.302 | -1.029 | -3.477 | -10.075 | -2,437.137 | 0 | -397.716 | -352.058 | -1,146.985 | -53.164 | -9.817 | -5.321 |
| EPS
| -1.46 | -2.72 | -3.5 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EPS Diluted
| -1.46 | -2.72 | -3.5 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EBITDA
| -158.853 | -263.626 | -285.688 | -231.228 | -154.012 | -162.267 | -98.834 | -115.324 | -105.814 | -30.683 | -26.214 | -16.317 |
| EBITDA Ratio
| -0.344 | -1.058 | -3.496 | -10.263 | -2,540.905 | 0 | -402.032 | -348.724 | -1,158.159 | -53.149 | -9.578 | -5.233 |